LSE:GSKPharmaceuticals
GSK’s New Designations And Approvals Shift Focus To Late Stage Pipeline
GSK (LSE:GSK) received Breakthrough Therapy designation from the US FDA and PRIME status from the EMA for its investigational liver therapy efimosfermin for MASH.
The company secured approval for Blenrep in China for the treatment of multiple myeloma.
Depemokimab gained expanded global regulatory approvals in respiratory diseases, broadening its reach across markets.
GSK, a global biopharma group focused on specialty medicines and vaccines, is increasingly centered on treatments for serious...